BridgeBio Pharma vs Mirum Pharmaceuticals
Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, about the same as BridgeBio Pharma's $502 million in fiscal 2025. BridgeBio Pharma's revenue grew 126.3% in its latest year, and Mirum Pharmaceuticals' grew 54.7%. BridgeBio Pharma had an operating margin of -104.2%, against -4.2% at Mirum Pharmaceuticals. Free cash flow was −$447 million at BridgeBio Pharma and $55 million at Mirum Pharmaceuticals.
Side by side
| BridgeBio Pharma | Mirum Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $502M | $521M |
| Revenue growth | 126.3% | 54.7% |
| Revenue growth a year, last 5 years | 127.7% | — |
| Gross margin | 95.8% | — |
| Operating margin | −104.2% | −4.2% |
| Net margin | −146.0% | −4.5% |
| Free cash flow | −$447M | $55M |
| Free cash flow margin | −89.0% | 10.5% |
| Return on capital | — | −7.1% |
| Net debt to EBITDA | — | −34.9x |
| Dividends and buybacks | $48M | $0M |
| Change in diluted share count | 2.9% | 5.6% |
| Last close | $78.18 | $95.51 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $86.2 million | bought $9.0 million, sold $43.1 million |
| Piotroski F-score | 3 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BridgeBio PharmaMirum Pharmaceuticals
Operating margin
Percent of revenue
BridgeBio PharmaMirum Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BridgeBio PharmaMirum Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BridgeBio Pharma and Mirum Pharmaceuticals pages.